Monica R. Maiello

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.

MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.

Journal: Cells
Published: March 30, 2026

Hormonally upregulated neu tumor-associated kinase (HUNK) modulates gastric cancer progression through the regulation of cell homeostasis.

Hormonally upregulated neu tumor-associated kinase (HUNK) modulates gastric cancer progression through the regulation of cell homeostasis.

Journal: Cell communication and signaling : CCS
Published: June 19, 2025

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.

Journal: Nature communications
Published: March 24, 2025

The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.

The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.

Journal: International journal of molecular sciences
Published: April 05, 2024

Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.

Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.

Journal: Journal for immunotherapy of cancer
Published: December 29, 2023

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics.

Journal: Diagnostics (Basel, Switzerland)
Published: June 09, 2022

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.

Journal: The oncologist
Published: February 10, 2021

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls.

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls.

Journal: Cancers
Published: November 11, 2020

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.

FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention.

Journal: International journal of molecular sciences
Published: July 31, 2020

Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.

Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.

Journal: Cancers
Published: June 19, 2020

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications.

Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications.

Journal: Translational lung cancer research
Published: March 25, 2020

The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells.

The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells.

Journal: Expert review of molecular diagnostics
Published: July 16, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026